FDA Finalizes Live Biotherapeutic Product Framework: What Practitioners Must Know in 2026

The FDA's finalized LBP guidance creates the first regulatory pathway distinguishing next-generation engineered probiotics from conventional supplements, with immediate clinical and liability implications for practitioners recommending microbiome-based interventions.